TheraRadar
← Back
Data updated: Jun 28, 2026

WATSON LABS INC

Generics
CardiovascularNeurologyInfectious Disease Execution: Excellent

WATSON LABS INC is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.

1971
Since
393
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

WATSON LABS INC at a Glance

  • Strong track record with 83% execution quality across 12 trials
  • Fast trial execution (9 months median completion)

WATSON LABS INC's Key Drugs

WATSON LABS INC's core commercial portfolio centers on DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, NORGESTIMATE; ETHINYL ESTRADIOL, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM
Women's Health

Premenstrual Dysphoric Disorder

Approved 2016
NORGESTIMATE; ETHINYL ESTRADIOL
Women's Health

Pregnancy prevention

Approved 2011

WATSON LABS INC's Recent FDA Approvals

WATSON LABS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

WATSON LABS INC's Therapeutic Areas

WATSON LABS INC's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 41%
28 drugs
Neurology 18%
12 drugs
Infectious Disease 15%
10 drugs
Dermatology 13%
9 drugs
Immunology 13%
9 drugs

WATSON LABS INC Pipeline Snapshot

Active clinical trials for WATSON LABS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/2 completed
  • • Speed: 9 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges